Health plans and employers are increasingly hesitant to cover GLP-1 drugs for weight loss due to high costs and patient discontinuation rates. A new report indicates that nearly half of employers not currently covering these drugs for obesity would not do so at any price. Concerns about affordability and long-term patient outcomes are driving these decisions, with some companies, like Cigna, ceasing coverage for weight loss while maintaining it for type-2 diabetes treatment. AI
RANK_REASON This article discusses trends in health plan coverage decisions for existing drugs, rather than a new release or significant industry shift.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
